Search research articles
Contact Us
Filters
Showing results (91-100 of 144) with videos related to
Page
of 15
Sort By:
Journal of the American College of Cardiology
|
April 25, 2006
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
James M McKenney, Michel Farnier, Kwok-Wing Lo, et al.
European Heart Journal
|
November 30, 2017
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Philip D Harvey, Marwan N Sabbagh, John E Harrison, et al.
Journal of the American Heart Association
|
September 15, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes, John R Guyton, Norman Lepor, et al.
American Heart Journal
|
January 24, 2007
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia
Michel Farnier, Eli Roth, Blas Gil-Extremera, et al.
Journal of Clinical Lipidology
|
April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
John J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
Journal of Clinical Lipidology
|
July 21, 2019
Prevalence, risk factor burden, and severity of coronary artery disease in patients with heterozygous familial hypercholesterolemia hospitalized for an acute myocardial infarction: Data from the French RICO survey
Michel Farnier, Clémence Salignon-Vernay, Hermann Yao, et al.
Cardiovascular Research
|
January 9, 2024
Negative relationship between eicosapentaenoic acid and inflammatory biomarkers in patients with acute myocardial infarction
David Masson, Damien Leleu, Michel Farnier, et al.
Progress in Cardiovascular Diseases
|
March 8, 2023
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Maciej Banach, Peter E Penson, Michel Farnier, et al.
Frontiers in Cardiovascular Medicine
|
June 22, 2026
Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins
Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, et al.
The American Journal of Cardiology
|
September 26, 2013
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
Harold E Bays, Maurizio Averna, Claudio Majul, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 144) with videos related to
Sort By:
Page
of 15
Journal of the American College of Cardiology
|
April 25, 2006
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia
James M McKenney, Michel Farnier, Kwok-Wing Lo, et al.
European Heart Journal
|
November 30, 2017
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Philip D Harvey, Marwan N Sabbagh, John E Harrison, et al.
Journal of the American Heart Association
|
September 15, 2016
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
Erik Stroes, John R Guyton, Norman Lepor, et al.
American Heart Journal
|
January 24, 2007
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia
Michel Farnier, Eli Roth, Blas Gil-Extremera, et al.
Journal of Clinical Lipidology
|
April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
John J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
Journal of Clinical Lipidology
|
July 21, 2019
Prevalence, risk factor burden, and severity of coronary artery disease in patients with heterozygous familial hypercholesterolemia hospitalized for an acute myocardial infarction: Data from the French RICO survey
Michel Farnier, Clémence Salignon-Vernay, Hermann Yao, et al.
Cardiovascular Research
|
January 9, 2024
Negative relationship between eicosapentaenoic acid and inflammatory biomarkers in patients with acute myocardial infarction
David Masson, Damien Leleu, Michel Farnier, et al.
Progress in Cardiovascular Diseases
|
March 8, 2023
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Maciej Banach, Peter E Penson, Michel Farnier, et al.
Frontiers in Cardiovascular Medicine
|
June 22, 2026
Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins
Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, et al.
The American Journal of Cardiology
|
September 26, 2013
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia
Harold E Bays, Maurizio Averna, Claudio Majul, et al.
Page
of 15